CL (cardiolipin) is a major mitochondrial membrane phospholipid important for the regulation of mitochondrial function. We examined CL de novo biosynthesis and its resynthesis in isolated rat liver hepatocytes prepared 48 h subsequent to two-thirds PHx (partial hepatectomy). The pool size of CL and its de novo biosynthesis from [1,3-3H]glycerol were increased 3.3-fold (P<0.05) and 3.1-fold (P<0.05) respectively in hepatocytes prepared from PHx rats compared with sham-operated controls. The reason for the increased CL biosynthesis was a 65% increase (P<0.05) in enzymic activity in PGP-S (phosphatidylglycerolphosphate synthase), a key enzyme in de novo CL biosynthesis. The increase in PGP-S activity was due to a 3-fold increase (P<0.05) of hepatic PGP-S mRNA expression. The increase in de novo CL biosynthesis and pool size corresponded to a 2.3-fold increase (P<0.05) in the amount of [1-14C]linoleic acid incorporated into CL of hepatocytes prepared from PHx rats compared with sham-operated controls, indicating an increase in CL resynthesis. The activity of MLCL-AT (monolysocardiolipin acyltransferase), a rate-limiting enzyme of CL resynthesis, was increased by 43% (P<0.05) in hepatocytes prepared from PHx rats compared with sham-operated controls; this result would explain the increase in [1-14C]linoleic acid incorporation into CL. The increase in MLCL-AT activity was due to an increase in hepatic MLCL-AT protein expression. The results show that CL de novo biosynthesis and its resynthesis are increased during liver regeneration.
Skip Nav Destination
Article navigation
February 2005
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Research Article|
February 08 2005
On the mechanism of the increase in cardiolipin biosynthesis and resynthesis in hepatocytes during rat liver regeneration
Jennifer WEBSTER;
Jennifer WEBSTER
*Department of Pharmacology and Therapeutics, Center for Research and Treatment of Atherosclerosis, University of Manitoba, Winnipeg, Canada R3E 0T6
Search for other works by this author on:
Jenny Y. JIANG;
Jenny Y. JIANG
*Department of Pharmacology and Therapeutics, Center for Research and Treatment of Atherosclerosis, University of Manitoba, Winnipeg, Canada R3E 0T6
Search for other works by this author on:
Biao LU;
Biao LU
*Department of Pharmacology and Therapeutics, Center for Research and Treatment of Atherosclerosis, University of Manitoba, Winnipeg, Canada R3E 0T6
Search for other works by this author on:
Fred Y. XU;
Fred Y. XU
*Department of Pharmacology and Therapeutics, Center for Research and Treatment of Atherosclerosis, University of Manitoba, Winnipeg, Canada R3E 0T6
Search for other works by this author on:
William A. TAYLOR;
William A. TAYLOR
*Department of Pharmacology and Therapeutics, Center for Research and Treatment of Atherosclerosis, University of Manitoba, Winnipeg, Canada R3E 0T6
Search for other works by this author on:
Mathew MYMIN;
Mathew MYMIN
*Department of Pharmacology and Therapeutics, Center for Research and Treatment of Atherosclerosis, University of Manitoba, Winnipeg, Canada R3E 0T6
Search for other works by this author on:
Manna ZHANG;
Manna ZHANG
†Department of Internal Medicine, Center for Research and Treatment of Atherosclerosis, University of Manitoba, Winnipeg, Canada R3E 0T6
Search for other works by this author on:
Gerald Y. MINUK;
Gerald Y. MINUK
*Department of Pharmacology and Therapeutics, Center for Research and Treatment of Atherosclerosis, University of Manitoba, Winnipeg, Canada R3E 0T6
†Department of Internal Medicine, Center for Research and Treatment of Atherosclerosis, University of Manitoba, Winnipeg, Canada R3E 0T6
Search for other works by this author on:
Grant M. HATCH
Grant M. HATCH
1
*Department of Pharmacology and Therapeutics, Center for Research and Treatment of Atherosclerosis, University of Manitoba, Winnipeg, Canada R3E 0T6
†Department of Internal Medicine, Center for Research and Treatment of Atherosclerosis, University of Manitoba, Winnipeg, Canada R3E 0T6
‡Department of Biochemistry and Medical Genetics, Center for Research and Treatment of Atherosclerosis, University of Manitoba, Winnipeg, Canada R3E 0T6
1To whom correspondence should be addressed, at Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg (email hatchgm@ms.umanitoba.ca).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
April 20 2004
Revision Received:
September 24 2004
Accepted:
September 30 2004
Accepted Manuscript online:
September 30 2004
Online ISSN: 1470-8728
Print ISSN: 0264-6021
The Biochemical Society, London
2005
Biochem J (2005) 386 (1): 137–143.
Article history
Received:
April 20 2004
Revision Received:
September 24 2004
Accepted:
September 30 2004
Accepted Manuscript online:
September 30 2004
Citation
Jennifer WEBSTER, Jenny Y. JIANG, Biao LU, Fred Y. XU, William A. TAYLOR, Mathew MYMIN, Manna ZHANG, Gerald Y. MINUK, Grant M. HATCH; On the mechanism of the increase in cardiolipin biosynthesis and resynthesis in hepatocytes during rat liver regeneration. Biochem J 15 February 2005; 386 (1): 137–143. doi: https://doi.org/10.1042/BJ20040655
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.